IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES

Clinical trials for IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES explained in plain language.

Never miss a new study

Get alerted when new IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES trials appear

Sign up with your email to follow new studies for IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug combo targets genetic flaw in aggressive blood cancers

Disease control Recruiting now

This study is testing whether adding the drug olutasidenib to standard chemotherapy can better control advanced blood cancers in patients who have a specific genetic mutation (IDH1). It aims to see if this combination is safe and effective at reducing the disease. The trial is fo…

Matched conditions: IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES

Get alerted when new IDH1-MUTATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES trials appear

New drug combo targets genetic flaw in aggressive blood cancers